Development and validation of a liquid chromatographic method for in vitro mupirocin quantification in both skin layers and percutaneous penetration studies

被引:24
作者
Echevarría, L
Blanco-Príeto, MJ
Campanero, MA
Santoyo, S
Ygartua, P [1 ]
机构
[1] Univ Navarra, Fac Farm, Dept Farmacia & Technol Farmaceut, Pamplona 31080, Spain
[2] Univ Navarra Clin, Serv Farmacol Clin, Pamplona 31080, Spain
[3] Univ Autonoma Madrid, Dept Ciencia & Tecnol ALimentos, Madrid, Spain
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 796卷 / 02期
关键词
skin recovery; mupirocin; PSEUDOMONIC ACID-A; ANTIBACTERIAL ACTIVITY; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; TOPICAL USE; MICROPARTICLES; SYNTHETASE; INFECTIONS; INHIBITION; RESISTANCE;
D O I
10.1016/j.jchromb.2003.07.011
中图分类号
Q5 [生物化学];
学科分类号
070307 [化学生物学];
摘要
A simple, rapid, and sensitive reversed-phase high-performance liquid chromatographic (HPLC) method for the measurement of mupirocin concentrations in both skin layers and percutaneous samples has been developed. Mupirocin was extracted from skin layers using PBS-acetonitrile (90:10, v/v). The method is sufficiently sensitive and repeatable to be used in percutaneous penetration studies. The samples were chromatographed on a 250 mm x 4 mm C-8 LiChrospher Select B (5 mum). The mobile phase composition was a mixture of acetonitrile-ammonium acetate 0.05 M (27.5:72.5, v/v) adjusted to pH 6.3 with acetic acid. The analyte was detected at 228 nm and the run time was 11 min. Linearity was confirmed in the concentration range 0.2-20 mug/ml and the limit of detection was 9.5 ng/ml. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 23 条
[1]
BORK K, 1989, BRIT J CLIN PRACT, V43, P284
[2]
The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice [J].
Cookson, BD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) :11-18
[3]
Topical application of acyclovir-loaded microparticles:: quantification of the drug in porcine skin layers [J].
de Jalón, EG ;
Blanco-Príeto, MJ ;
Ygartua, P ;
Santoyo, S .
JOURNAL OF CONTROLLED RELEASE, 2001, 75 (1-2) :191-197
[4]
Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA) [J].
Eltringham, I .
JOURNAL OF HOSPITAL INFECTION, 1997, 35 (01) :1-8
[5]
Efficacy of a new cream formulation of mupirocin: Comparison with oral and topical agents in experimental skin infections [J].
Gisby, J ;
Bryant, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :255-260
[6]
MODE OF ACTION OF PSEUDOMONIC ACID - INHIBITION OF PROTEIN-SYNTHESIS IN STAPHYLOCOCCUS-AUREUS [J].
HUGHES, J ;
MELLOWS, G .
JOURNAL OF ANTIBIOTICS, 1978, 31 (04) :330-335
[7]
INTERACTION OF PSEUDOMONIC ACID-A WITH ESCHERICHIA-COLI B-ISOLEUCYL-TRANSFER RNA-SYNTHETASE [J].
HUGHES, J ;
MELLOWS, G .
BIOCHEMICAL JOURNAL, 1980, 191 (01) :209-219
[8]
INHIBITION OF ISOLEUCYL-TRANSFER RIBONUCLEIC-ACID SYNTHETASE IN ESCHERICHIA-COLI BY PSEUDOMONIC ACID [J].
HUGHES, J ;
MELLOWS, G .
BIOCHEMICAL JOURNAL, 1978, 176 (01) :305-318
[9]
HOW DOES PSEUDOMONAS-FLUORESCENS, THE PRODUCING ORGANISM OF THE ANTIBIOTIC PSEUDOMONIC ACID-A, AVOID SUICIDE [J].
HUGHES, J ;
MELLOWS, G ;
SOUGHTON, S .
FEBS LETTERS, 1980, 122 (02) :322-324
[10]
STABILITY OF MUPIROCIN OINTMENT (BACTROBAN) ADMIXED WITH OTHER PROPRIETARY DERMATOLOGICAL PRODUCTS [J].
JAGOTA, NK ;
STEWART, JT ;
WARREN, FW ;
JOHN, PM .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1992, 17 (03) :181-184